What it is
BPC-157 is a synthetic pentadecapeptide derived from a sequence found in human gastric juice. Studied extensively in rodent in vivo and cell-culture models across vascular, tendon, gastrointestinal, and cytoprotective endpoints.
Evidence snapshot
Category: Tissue Repair. Status: Preclinical. See the references section below for the underlying primary sources.
Mechanism
Most consistently reported mechanisms include VEGF-driven angiogenesis, NO-system modulation (eNOS activity), fibroblast growth factor and EGF pathway interaction, and increased extracellular matrix synthesis. The compound is sometimes described as pleiotropic.
Key research findings
Across 140+ preclinical studies, BPC-157 has been reported to accelerate tendon healing in rat Achilles transection models, protect gastric mucosa against NSAID and ethanol-induced lesions, improve vascularisation in ischemic tissue, and counteract NO synthase inhibitor effects.
Limits of the evidence
No large peer-reviewed human clinical trials of BPC-157 have been published. Off-label human use is widespread despite the absence of approved human safety or efficacy data. Earlier studies (1990s–2000s) frequently lack modern reporting standards.